Latest News and Press Releases
Want to stay updated on the latest news?
-
スイス・ホルゲンおよび東京発, Nov. 14, 2025 (GLOBE NEWSWIRE) -- 免疫学および腫瘍学における多特異性抗体の独自のパイプラインを推進するバイオテクノロジー企業であるヌマブ・セラピューティクスAG (Numab Therapeutics AG) (「ヌマブ」) と、日本の研究開発主導型製薬企業である科研製薬株式会社 (Kaken Pharmaceutical...
-
HORGEN, Switzerland and TOKYO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology...
-
Numab to receive first milestone payment Boehringer Ingelheim has advanced its novel tumor antigen targeting T cell engager resulting from a collaboration with Numab into preclinical...
-
HORGEN, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and...
-
CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and...
-
ヌマブがND081の前臨床開発のための研究開発資金を受け取る 科研製薬は、臨床POCまでのグローバル開発資金と引き換えに、特定のアジア地域でND081のライセンスを取得するオプションを受け取る スイス・ホルゲンおよび東京発, Nov. 16, 2024 (GLOBE NEWSWIRE) --...
-
Numab to receive R&D funding for the preclinical development of ND081 Kaken Pharmaceutical receives an option to in-license ND081 in certain Asian territories in exchange for funding global...
-
NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies Low molecular...
-
ジョンソン・エンド・ジョンソンは、アトピー性皮膚炎の治療およびその後の適応症向けにNM26を世界的に開発、製造、商業化する完全な権利を取得。 契約条件に基づき、ジョンソン・エンド・ジョンソンはNM26の権利を保有するイエロージャージー・セラピューティクスを買収に12億5,000万米ドル (約1,959億1,687万円) を支払う ...
-
Numab Therapeutics Announces J&J to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for AD